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REACTIVITY OF HUMAN 
SAPHENOUS VEINS AT 
ARTERIAL PERFUSION 
PRESSURES 
Vasospasm of human saphenous vein grafts has been reported after 
aorta-coronary b pass operations. However, it is unknown whether veno- 
arterial grafts are inherently responsive to vasoconstrictor stimuli after 
implantation into the arterial circulation or whether their vasomotion is
secondary to hemodynamic changes. Thus in this study we used in vitro 
methods to directly evaluate whether isolated human saphenous vein 
segments respond to vasoconstrictor agents at arterial pressure levels. 
External diameter and intraluminal flow were monitored in 12 human 
saphenous vein segments, which were perfused at 30 ml/min with physio- 
logic salt solution at 90, 70, and 50 mm Hg. Increasing intraluminai 
pressure higher than 50 mm Hg or exposing the vein to Ca2+-free media did 
not increase vessel external diameter or intraluminal f ow, which suggests 
that human saphenous veins were fully distended at pressures of 50 mm Hg 
or greater. However, all human saphenous veins were activated by a 1 
/xmol/L dose of norepinephrine at 50 mm Hg and dilated during subsequent 
intraluminal infusion of a 1 /xmol/L dose of acetylcholine, showing intact 
vascular smooth muscle and endothelial cell function. In the same vessels, 
a 1 /xmol/L concentration of 5-hydroxytryptamine constricted human 
saphenous veins by 19%, 22%, and 26% at intraluminal pressures of 90, 70, 
and 50 mm Hg, respectively, and reduced vessel flow by 6%, 24%, and 42% 
at the same pressure levels. Similarly, a 1 /xmol/L concentration of 
norepinephrine constricted vessels pressurized at 90, 70, and 50 mm Hg by 
9%, 12%, and 17%, respectively, and attenuated vessel flow by as much as 
32%. We conclude that human saphenous vein segments are fully distended 
at perfusion pressures greater than 50 mm Hg, but can dynamically 
constrict o vasoactive agonists and regulate graft flow at intraluminal 
pressures as high as 90 mm Hg. Our findings in isolated human saphenous 
vein segments lend support o clinical observations that human saphenous 
vein grafts should be regarded as vasoactive conduits after implantation at 
arterial pressure levels. (J THORAC CARDIOVASC SURG 1995;110:1005-12) 
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A lthough aorta-coronary surgery with saphenous vein bypass grafting is an established procedure, 
surprisingly little is known about the contractile 
behavior of human saphenous vein (HSV) grafts at 
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arterial pressures. HSV grafts are commonly de- 
picted as inert conduits incapable of vasomotion. 1-3 
However, a growing number of clinical reports 
suggest that vasospasm of implanted HSV provokes 
angina, hypotension, and ventricular fibrillation in 
patients after aorta-coronary bypass operations 4-6 
and also occurs in patients after long-term implan- 
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Fig. 1. Apparatus used to measure De and intraluminal flow in pressurized, perfused HSV segments. 
tation of these grafts. 7-13 Furthermore, vasospasm of 
HSV grafts may contribute to early graft closure, 
perhaps as a result of disruption of the endothelial 
cell layer during severe vessel constriction, s This 
may compound the endothelial trauma induced by 
surgical procedures during graft preparation. 14-16 
Because spasm of HSV grafts has been implicated in 
the postoperative morbidity of aorta-coronary by- 
pass operations, it is important to evaluate the 
vasoconstrictor capabilities of these vessels to puta- 
tive spasmogens at arterial pressure levels. 
In this regard, earlier investigators have used 
angiographic methods to assess the vasoactivity of 
permanently implanted HSV grafts. 1' 1%19 Several 
studies suggest that the diameters of implanted 
grafts are insensitive to the dilating effects of tachy- 
cardia and local infusion of nitrates, implying that 
they are fully distended at arterial blood pressure 
levels and lack intrinsic vasomotor tone. 17' 18, 20 Nev- 
ertheless, Hanet, Robert, and Wijns 2° recently re- 
ported that although implanted HSV grafts were 
devoid of inherent vasomotor tone, they constricted 
strongly to infusion of ergonovine, suggesting that 
these vessels actively regulate their diameter after 
implantation into the arterial circulation, is How- 
ever, evaluating the direct effect of vasoconstrictor 
drugs on implanted graft reactivity is difficult, be- 
cause the inherent reactivity responses of the graft 
may be masked by concurrent changes in hemody- 
namic variables, L 19 All alternative approach is to 
use in vitro perfusion methods to directly record the 
vasoreactivity of isolated, cannulated segments of 
HSV. In the current study, we used this method to 
assess whether diameter and intraluminal flow of 
HSV segments are regulated by vasoconstrictor 
stimuli at arterial pressure levels. 
Methods 
Vein preparations. Distal segments of HSV from aorta- 
coronary bypass operations were obtained immediately 
after vein removal and before procedures for graft prep- 
aration. The vessel segments were transported to the 
laboratory in cold Plasma-Lyte solution (Baxter Health- 
care Corp., Deerfield, Ill.) and handled according to the 
standards of the institutional pathogen committee. Vein 
segments were classified as surgical specimens and were 
exempted by the institutional human review board from 
patient consent requirements. Vessel segments were from 
12 male patients (11 white, I black) with an average age of 
66 - 3 years (range 49 to 73 years). All veins were briefly 
cleaned of loose adventitial tissue with care taken to 
preserve vascular endothelium and smooth muscle cell 
layers. 
In vitro vessel perfusion. Vein segments (length 2.5 to 
3 cm) were placed in a vascular perfusion chamber 
(volume 25 ml) and superfused with a physiologic salt 
solution (PSS) at 5 ml/min by a small peristaltic pump. 
The vessel ends were mounted on opposing cannulas for 
intraluminal perfusion and pressurization (Fig. 1). Be- 
cause the in situ length of the vein segments was unknown, 
vessel ength was adjusted by separating the mounting 
cannulas until the vessel was linearly extended and 
showed no lateral bowing during pressurization. Side 
branches were secured with 5-0 silk ties and the vein was 
pressurized to50 mm Hg and independently perfused with 
PSS at 30 ml/min from a reservoir. External diameter (De) 
was monitored by a continuous on-line video technique 
described in detail elsewhere, 2~and data were acquired by 
CODAS software (Dataq Instruments, Akron, Ohio) and 
stored on a computer for analysis. Although this imaging 
technique also permits resolution of internal diameter in 
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small vessels, the thick wall of the HSV precluded visual- 
ization of internal dimensions in this study. 
Veins were perfused at nonoscillating pressures, and 
mean intraluminal flow was monitored by collection of 
the outflow perfusate in a calibrated cylinder. Although 
the nonoscillating flow pattern used in this study differs 
from the pulsatile flow pattern found in vivo, pressure- 
flow curves are reportedly similar between HSV seg- 
ments perfused by pulsatile and nonpulsatile pressure 
patterns. 3 Flow was adjusted by regulating an outflow 
resistor distal to the vessel. Inflow and outflow pres- 
sures were measured continuously by pressure trans- 
ducers and were regulated by adjusting the height of the 
reservoir containing the PSS perfusate. In drug-free 
PSS, inflow and outflow pressures were the same, 
suggesting that the cannula tips and vein diameter did 
not offer significant resistance to perfusate flow. The 
PSS perfusate and superfusate were composed of (in 
millimoles per liter) NaC1 119, KC1 4.7, MgSO4 1.17, 
CaC1 z 1.6, NaH2PO 4 1.18, NaHCO 3 24, ethylenediami- 
netetraacetic acid 0.026, and glucose 5.5. PSS was 
maintained at 37 ° C and aerated with a gas mixture 
composed of 15% 02, 7% CO2, and 78% N 2 to maintain 
pH at 7.4 in the perfusion and reservoir chambers. 
Measurements of graft reactivity. After the vessels 
were mounted, segments were perfused at 30 ml/min for 1 
hour to permit equilibration at an intraluminal pressure of 
50 mm Hg and to allow time for drug washout. Vascular 
reactivity was assessed in all vessels (n = 12) by verifying 
the ability of the vein to contract o superfusi0n with 
norepinephrine, 1 txmol/L. Endothelial function also was 
verified in each segment by demonstrating that norepi- 
nephrine-contracted v ssels dilated in response to intralu- 
minal perfusion of acetylcholine, 1 t~mol/L. Vessels were 
then perfused (30 ml/min) and superfused with drug-free 
PSS to reestablish basal D e and flow values for 30 minutes. 
In 6 of the 12 HSV segments, we tested for the presence 
of inherent vasomotor tone by comparing D e and flow 
changes (1) in vessels pressurized at 50 mm Hg and 
perfused and superfused with PSS to establish baseline 
values, (2) in vessels pressurized at 90 mm Hg and 
perfused and superfused with PSS, and (3) in vessels 
pressurized at 90 mm Hg and perfused and superfused 
with a Ca 2+- free PSS to abolish active tone. The compo- 
sition of the Ca2+-free PSS was (in millimoles per liter) 
NaC1 92, KC1 4.7, MgSO 4 1.2, MgC12 20, NaHCO 3 24, 
NaH2PO 4 1.18, ethylenediaminetetraacetic ac d 0.026, 
and glucose 5.5. 22 
Reactivity to vasoconstrictor agonists. In the remain- 
ing six veins in which smooth muscle and endothelial 
function were evaluated, we examined whether vessels 
were responsive to norepinephrine and 5-hydroxytryptamine 
(5-HT) at arterial pressure levels. HSV segments were 
equilibrated at an intraluminal pressure of 90 mm Hg, 
perfused with PSS at 30 ml/min, and superfused with drug- 
free PSS. Vessel D e and flow changes induced by superfu- 
sion with a 1/zmol/L dose of norepinephrine or a 1 txmol/L 
dose of 5-HT were measured at 90 mm Hg and then during 
stepwise pressure reductions from 90 mm Hg to 70 and 50 
mm Hg in the continued presence of the vasoconstrictor 
drug. 
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Fig. 2. A, Effects of norepinephrine (NE) and acetylcholine 
(ACH) on diameter (De) of HSV pressurized at 50 mm Hg 
and perfused at 30 ml/min. Original tracing shows that 
superfusion with a 1/zmol/L dose of norepinephrine r duced 
D e from 3.68 mm to 2.52 mm, whereas intraluminal perfu- 
sion of a 1 /xmol/L dose of acetylcholine partially reversed 
this constriction. B, Bar graph showing mean diameter of six 
HSV perfused and superfused (1) with PSS at 50 mm Hg, (2) 
with PSS at 90 mm Hg, and (3) with Ca2÷-free PSS at 90 mm 
Hg. Diameter was not increased by increasing pressure or by 
Ca2+-free PSS, implying that veins were already fully dis- 
tended at 50 mm Hg. 
Drugs. Norepinephrine, 5-HT, and acetylcholine were 
obtained from Sigma Chemical Company (St. Louis, 
Mo.). All drugs were prepared as 1 mmol/L aqueous tock 
solutions, which were added by aliquot directly to the 
perfusate or superfusate PSS to obtain the final drug 
concentrations. 
Statistics. Data are expressed as mean plus or minus 
the standard error of the mean. Statistical comparisons 
were done by analysis of variance with repeated measures. 
Significant differences between specific means were deter- 
mined by Duncan's new multiple range test. A value of 
p < 0.05 was considered significant. 
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Fig. 3. Original traces howing effects of norepinephrine (NE) and 5-HT on diameter (De) of two different 
HSV segments (vein 1, top traces; vein 2, lower traces). Veins initially were perfused with PSS at 30 ml/min 
at 90 mm Hg and then superfused with either norepinephrine (l ft traces) or 5-HT (right traces). During 
drug superfusion, intraluminal pressure was decreased from 90 mm Hg to 70 and 50 mm Hg. 
Results 
Graft viability and vasomotor tone. Fig. 2, A, 
shows an on-line recording of D e from an isolated 
HSV superfused with norepinephrine, 1 /,mol/L, 
and subsequently perfused with acetylcholine, 1
tzmol/L, to test for endothelium-dependent relax- 
ation. At an intraluminal pressure of 50 mm Hg, 
average resting D e was 3.54 ___ 0.14 mm in 12 veins. 
In the same vessels, superfusion with a 1 txmol/L 
concentration f norepinephrine r duced control D e 
by 17% to 2.93 _+ 0.16 mm, which verified the 
presence of contractile vascular smooth muscle 
cells. Subsequent intraluminal perfusion with acetyl- 
choline, 1 txmol/L, dilated vessels by 38% (n = 12), 
which indicated viability of the endothelial cell layer. 
In a subset of six vessels, we tested whether isolated 
HSVs showed resting vasomotor tone in the arterial 
pressure range between 50 and 90 mm Hg. Fig. 2, B, 
shows that vein D e measured in vessels perfused at 
30 ml/min and maintained at an intraluminal pres- 
sure of 50 mm Hg averaged 3.58 ___ 0.22 mm. When 
intraluminal pressure was increased to 90 mm Hg by 
elevation of the perfusion reservoir for 30 minutes, 
graft D e and flow were unchanged. Similarly, vessel 
D e and flow also were unaffected by 30 minutes of 
vessel perfusion and superfusion with Ca 2+-free PSS 
to abolish active vascular tone, which indicated that 
HSVs were fully distended and devoid of resting 
vasomotor tone at pressures of 50 mm Hg or 
greater. 
Reactivity to vasoconstrictor agonists. We as- 
sessed the vasoconstrictor effects of norepinephrine 
and 5-HT on vessel D e and flow at 90 mm Hg and 
then during stepwise, acute decreases in intralumi- 
nal pressure from 90 mm Hg to 70 and 50 mm Hg. 
Continuous recordings of D e in two different HSV 
segments are shown in Fig. 3. Veins that were 
initially equilibrated at 90 mm Hg and perfused (30 
ml/min) and superfused with drug-free PSS for 30 
minutes showed an average D e control value of 
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Fig. 4. Effect of a 1 /xmol/L dose of norepinephrine (NE) on diameter (De) and intraluminal flow of six 
HSVs at 90 mm Hg and during stepwise pressure changes to 70 and 50 mm Hg. A, Bar graph of mean D~. 
B, Bar graph of flow changes to norepinephrine. Open bars (control) represent values in veins perfused with 
PSS at 30 ml/min at 90 mm Hg and superfused with drug-free PSS. Filled bars signify responses to a 1 
ixmol/L dose of norepinephrine as percent of control. Asterisk indicates ignificant difference from control 
value. Control diameter and flow at 90 mm Hg in drug-free PSS were 3.59 + 0.17 mm and 30 ml/min, 
respectively. 
3.59 +_ 0.17 mm. Superfusion with norepinephrine 
(Fig. 3, left traces) or with 5-HT (Fig. 3, right traces), 
both in concentrations of 1 txmol/L, actively con- 
stricted all vessels pressurized at 90 mm Hg. Some 
HSV segments were only moderately responsive to 
vasoconstrictors at 90 mm Hg (vein 1), whereas 
other vessels showed intense constrictor responses 
at this pressure (vein 2). When perfusion pressure 
was acutely lowered from 90 mm Hg to levels of 70 
and 50 mm Hg, the constrictions to norepinephrine 
and 5-HT were enhanced (Fig. 3). Fig. 4, A, shows 
that compared with results in HSV segments per- 
fused at 90 mm Hg in PSS (control veins), superfu- 
sion with a 1/xmol/L dose of norepinephrine signif- 
icantly reduced vein De at 90, 70, and 50 mm Hg by 
9% _+ 2%, 12% _+ 3%, and 17% _+ 3%, respectively 
(n = 6). In the same vessels, norepinephrine did not 
significantly reduce flow at 90 mm Hg, but it mark- 
edly decreased flow by 13% _+ 4% and by 32% _+ 
3% at 70 and 50 mm Hg, respectively (Fig. 4, B). 
5-HT was a more potent vasoconstrictor than nor- 
epinephrine, as shown by the bar graphs in Fig. 5, A 
and B (n = 6). This agonist attenuated D e and flow 
in HSV segments perfused at 90 mm Hg by 19% +_ 
6% and 6% - 1%, respectively, and these responses 
were potentiated when pressure was lowered to 70 
and 50 mm Hg. The averaged ata show that 5-HT 
attenuated vessel D e and flow by 23% + 7% and 
24% +_ 7%, respectively, at 70 mm Hg and by 
26% _-2- 7% and 42% + 6%, respectively, at 50 mm 
Hg. Norepinephrine-induced responses averaged 
about 40% less in the same veins at the lower 
pressures. Stepwise lowering of intraluminal pres- 
sure during norepinephrine and 5-HT exposure also 
induced a fall in outflow (but not inflow) pressure in 
five of six veins, which suggests that venous contrac- 
tion to agonists was partially occluding internal 
vessel diameter. 
Discuss ion  
The main goal of this study was to determine 
whether isolated HSV segments actively respond to 
vasoconstrictor stimuli at arterial perfusion pres- 
sures. In this respect, our findings provide the first 
evidence that HSVs are inherently vasoactive con- 
duits at arterial pressure levels that can dynamically 
regulate their flow in response to endogenous vaso- 
constrictor substances. Our study also confirms the 
findings of Dobrin and colleagues, 3 who reported 
that HSV segments lack resting vasomotor tone and 
behave as rigid tubes at intraluminal pressures 
higher than 50 mm Hg. Chronically implanted HSV 
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Fig. 5. Effect of a 1/zmol/L dose of 5-HT on diameter (De) and intraluminal flow of six HSVs at 90 mm 
Hg and during stepwise pressure changes to 70 and 50 mm Hg. A, Bar graph of mean De. B, Bar graph of 
flow changes to 5-HT. Open bars (control) represent values in veins perfused with PSS at 30 ml/min at 90 
mm Hg and superfused with drug-free PSS. Filled bars ignify responses to a 1 /~mol/L dose of 5-HT as 
percent of control value. Asterisk indicates ignificant difference from control value. Plus sign indicates 
significant difference from same measurement i  norepinephrine superfusate (Fig. 4, A and B). Control 
diameter and flow at 90 mm Hg in drug-free PSS were 3.59 _+ 0.20 mm and 30 ml/min, respectively. 
grafts also reportedly lack inherent vasomotor 
tone,17, 18, 20 but our findings in fresh HSVs may not 
be applicable to long-term grafts that show altered 
responsiveness to contractile agonists after implan- 
tation. 23-26 It also should be acknowledged that our 
values for D e are not quantitatively coupled to flow 
alterations, because flow through a conduit is an 
inverse function of the fourth power of the internal 
radius, and we were limited to imaging external vein 
dimensions in this study. In addition, Poiseuille's law 
states that flow is inversely proportional to conduit 
length, and thus for the same levels of constriction, 
flow through our HSV segments likely decreased 
less than would be expected for longer aorta-coro- 
nary vein conduits. 
Vasoconstrictor sensitivity. Our findings that 
HSVs actively contract to vasoconstrictor agonists at 
intraluminal pressures as high as 90 mm Hg contrast 
with those of Dobrin and colleagues, 3 who evaluated 
the biomechanical properties of HSV segments in a 
cannulated vessel preparation. In their report, HSV 
pressurized at 100 mm Hg showed only a 3% 
constriction in response to supramaximal doses of 
norepinephrine, 3 whereas at the slightly lower pres- 
sure of 90 mm Hg we observed a 17% constriction to 
a lower norepinephrine concentration. The reason 
for this difference is not readily apparent, but may 
relate to different vessel sizes or to differing methods 
of vessel preparation. 27 The other authors used 
HSV segments of larger diameter (D e of 4.7 mm 
compared with 3.5 mm in this study) and, because 
their study focused on the biophysical effects of 
intraluminal f ow, they used 100% oxygen to initially 
inflate HSV segments to detect vessel eaks. 3 How- 
ever, similar applications of air boluses remove 
vascular endothelial cells and reduce vascular tone 
in some cannulated vessel preparations. 28 In con- 
trast, because our study focused on evaluating the 
biologic responses of HSV, we avoided air perfusion 
and handled vessels cautiously to minimize endothe- 
lial or vascular smooth muscle damage. By this 
method, all HSV in our study constricted to norepi- 
nephrine and 5-HT and also showed levels of ace- 
tylcholine-induced ilation comparable to those 
previously measured in HSV mounted for tension- 
recording studies. 28' 29 
It should be noted that the 1 /xmol/L concentra- 
tions of norepinephrine and 5-HT used in this study 
represent physiologic levels of these vasoactive ago- 
nists, which only submaximally activate HSV seg- 
ments.3O, 31 For instance, intravascular norepineph- 
rine concentrations a high as 100/zmol/L have been 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 110, Number 4, Part 1 
Rusch et aL 1011 
reported in innervated blood vessels, 32 whereas 
5-HT concentrations approaching 1 txmol/L have 
been measured in the effluent from aggregating 
human platelets. 33 Although the same norepineph- 
rine and 5-HT concentrations of 1 /xmol/L were 
used in each experiment, the intensity of vessel 
responses to vasoactive drugs was variable between 
veins. This variability in vascular eactivity between 
vessel segments may be attributed to different ages, 
genetic profiles, and drug regimens of the patients, 
as well as to the inherent condition of the vein and 
the surgical handling of the vessel. 
Importantly, our results support he concept hat 
5-HT is a powerful vasoconstrictor f HSV grafts 
and a candidate mediator of vasospasm. 29 In our 
studies, 5-HT reduced D e and flow of all HSV 
segments perfused at 90 mm Hg, an effect that was 
greatly accentuated when pressure was lowered to 
70 and 50 mm Hg. The mechanism for this enhanced 
diameter esponse to 5-HT at lower pressures was 
not passive vessel deflation, because vein De was not 
less at 50 than at 90 mm Hg in agonist-free PSS (Fig. 
1, B). Rather, our data suggest hat although HSVs 
are fully distended between 50 and 90 mm Hg, 5-HT 
is capable of activating venous muscle cells to sur- 
mount distending pressures as high as 90 mm Hg, 
and this activation is more apparent at lower pres- 
sures. Norepinephrine also was an effective vasocon- 
strictor agent, although it only significantly reduced 
HSV flow at the lower pressures of 70 and 50 mm 
Hg. This finding is consistent with those of reports 
from tension-recording studies that norepinephrine 
is a weaker spasmogen than 5-HT in HSVs. 29 
Ilypotension, graft reactivity, and clinical impli- 
cations. Isolated HSV segments in this study con- 
stricted more strongly to norepinephrine and 5-HT 
when intraluminal pressures were reduced from 90 
mm Hg to levels of 70 or 50 mm Hg. This enhanced 
vasoconstriction at lower arterial pressures may be 
interpreted as a mechanism for greater susceptibility 
to graft vasospasm in patients howing hypotension 
after aorta-coronary bypass operations. Hypoten- 
sion is a common complication after aorta-coronary 
bypass procedures, 34when circulating levels of nor- 
epinephrine and 5-HT are increased and platelet 
aggregation at the graft site may enhance local 
concentrations of 5-HT. 6' 35 Our study raises the 
possibility that in the postoperative period the pres- 
ence of high levels of vasoconstrictor agonists cou- 
pled with systemic hypotension may contribute to 
the induction of graft vasospasm, which can trigger 
angina and lethal ventricular arrhythmias in some 
patients. 4-13 However, in other patients, unless there 
is spasm of the recipient artery in conjunction with 
vein spasm, graft vasospasm ay go undetected in 
the postoperative period. 6In these cases, the vascu- 
lar damage induced by silent episodes of severe 
vasospasm ay present as graft thrombosis at a later 
date.5.6, 10 
We thank Ms. Luellen Lougee of LabRat Graphix for 
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